AUS
NZ
UK
CA
USA
IND
Highlights
- In the Phase 1B clinical trial with CHM 1101, the first patient has been dosed.
- The Phase 1B trial is built upon the recently reported positive data from the Phase 1A clinical trial,
- The Phase 1B trial assesses CHM 1101 in patients with progressive or recurrent glioblastoma.
Chimeric Therapeutics Limited (ASX: CHM) informed that the first patient in the Phase 1B recurrent/progressive glioblastoma multiforme (GBM) clinical trial has been dosed with CHM 1101 CAR T cell therapy.
Data source: Company update
Shares up over 3%
CHM shares traded at AU$0.030 apiece at the time of writing on 2 November 2023, up more than 3.4% from the last close.
